The IGF axis and programmed cell death

Immunology and Cell Biology

Volumn 77, Issue 3, 1999, Pages 256-262

  Butt, Alison J ^a   Firth, Sue M ^a   Baxter, Robert C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Apoptosis; Insulin like growth factor binding protein 3; Insulin like growth factor 1; p53; Survival factors

Indexed keywords

PROTEIN P53; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN;

APOPTOSIS; CARCINOGENESIS; CELL SURVIVAL; CONFERENCE PAPER; HUMAN; NONHUMAN; SIGNAL TRANSDUCTION; STRESS;

ANIMALS; APOPTOSIS; CELL DIVISION; CELL SURVIVAL; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; SOMATOMEDINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032973417     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1999.00822.x     Document Type: Conference Paper

References (76)

1. 1 Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr. Rev. 1989; 10: 68-91.
2. 2 Ullrich A, Gray A, Tam AW et al. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define hormonal specificity. EMBO J. 19R6; 5: 2503-12.
3. 3 Kalo H, Faria TN, Stannard N, Roberts CT, LeRoith D. Role of the tyrosine kinase domain in signal transduction by the insulin-like growth factor-I receptor. J. Biol. Chem. 1993; 268: 2655-61.
4. 4 LeRoith D, Werner H, Beitner-Johnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 1995; 16: 143-63.
5. 5 Roth RA. Structure of the receptor for insulin-like growth factor II: The puzzle amplified. Science 1988; 239: 1269-71.
6. 6 Kornfeld S. Structure and function of the mannose 6-phosphate/insulin-like growih factor II receptors. Annu. Rev. Biochem. 1992; 61: 307-30.
7. 7 Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr. Rev. 1995; 16: 3-34.
8. 8 Yee D, Paik S, Lebovic GS et al. Analysis of IGF-I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol. Endocrinol. 1989; 3: 509-17.
9. 9 Cullen KJ, Lippman ME, Chow D, Hill S, Rosen N, Zwiebel JA. Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol. Endocrinol. 1992; 6: 91-100.
10. 10 Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A, Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-I) and type 1 IGF receptor (IGF1R). Cell 1993; 75: 59-72.
11. 11 Shimasaki S, Ling N. Identification and molecular characterisation of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5, and -6). Prog. Growth Factor Res. 1991; 3: 243-66.
12. 12 Baxter RC. Insulin-like growth factor binding proteins in the human circulation: A review. Horm. Res. 1994; 42: 140-4.
13. 13 Sell C, Baserga R, Rubin R, Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res. 1995; 55: 303-6.
14. 14 Lamm GM, Christofori G. Impairment of survival factor function potentiates chemotherapy-induced apoptosis in tumor cells. Cancer Res. 1998; 58: 801-7.
15. 15 Harrington EA, Bennett MR, Fanidi A, Evan GI. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 1994; 13: 3286-95.
16. 16 Rodriguez-Tarduchy G, Collins MKL, Garcia I, Lopez-Rivas A. Insulin-like growth factor-I inhibits apoptosis in IL-3 dependent haemopoietic cells. J. Immunol. 1992; 149: 535-40.
17. 17 Muta K, Krantz SB. Apoptosis of human crythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor I as well as erythropoietin. J. Cell. Physiol. 1993; 156: 264-71.
18. 18 Harrison M, Dunger AM, Berg S et al. Growth factor protection against cytokine-induced apoptosis in neonatal rat islets of Langerhans: Role of Fas. FEBS Lett. 1998; 435: 207-10.
19. 19 Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. 1997; 17: 1595-606.
20. 20 Stewart CE, Rotwein P. Insulin-like growth factor-II is an autocrine survival factor for differentialing myoblasts. J. Biol. Chem. 1996; 271: 11 330-8.
21. 21 Rininsland F, Johnson TR, Chernicky CL, Schulze E, Burfeind P, Han J. Suppression of insulin-like growth factor type 1 receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc. Natl Acad. Sci. USA 1997; 94: 5854-9.
22. 22 Yin DL, Pu I., Pei G. Antisense oligonucleotide to insulin-like growth factor II induces apoptosis in human ovarian cancer AO cell line. Cell Res. 1998; 8: 159-65.
23. 23 Petrik J, Arany E, McDonald TJ, Hill DJ. Apoptosis in the pancreatic islet cells of the neonatal rat is associated with a reduced expression of insulin-like growth factor II that may act as a survival factor. Endocrinology 1998; 139: 2994-3004.
24. 24 Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994; 369: 414-18.
25. 25 Neuenschwander S, Schwartz A, Wood TL, Roberts CT, Henninghausen L, LeRoith D. Involution of the lactating mammary gland is inhibited by the IGF system in transgenic mouse model. J. Clin. Invest. 1996; 97: 2225-32.
26. 20 Resnicoff M, Burgaud J-L, Rotman HL, Abraham D, Baserga R. Correlation between apoptosis, tumorigenesis and levels of insulin-like growth factor I receptors. Cancer Res. 1995; 55: 3739-41.
27. 27 O'Connor R, Kauffmann-Zeh A, Lin Y et al. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol. Cell. Biol. 1997; 17: 427-35.
28. 28 Liu Y, Lehar S, Corvi C, Payne G, O'Connor R. Expression of the insulin-like growth factor I receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells. Cancer Res. 1998; 58: 570-6.
29. 29 Kauffman-Zch A, Rodriguez Viciana P, Ulrichy F. et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997; 385; 544-8.
30. 30 Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor I inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activaled protein kinasc pathways. J. Biol. Chem. 1997; 272: 154-61.
31. 31 Kulik G, Weber MJ. Akt-dependent and -independent survival signalling pathways utilized by insulin-like growth factor I. Mol. Cell. Biol. 1998; 18: 6711-18.
32. 32 Mabley JG, Belin V, John N, Green IC. Insulin-like growth factor I reverses interleukin-1β inhibition of insulin secretion, induction of nitric oxide synthase and cytokine-mediated apoptosis in rat islets of Langerhans. FEBS Lett. 1997; 417: 235-8.
33. 1 gene product. Endocrinology 1997; 138: 1355-8.
34. 34 Singleton JR, Dixit VM, Feldman EL. Type 1 insulin-like growth factor receptor activation regulates apoptotic proteins. J. Biol. Chem. 1996; 271: 31 791-4.
35. 35 Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN. Transduction of interleukip-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc. Natl Acad. Sci. USA 1997; 94: 3627-32.
36. 1. J. Neurosurg. 1998; 88: 884-9.
37. 37 Suzuki J, Kaziro Y, Koide H. Synergistic action of R-Ras and IGF-I on Bcl-xL expression and caspase-3 inhibition in BaF3 cells: R-Ras and FGF-I control distinct anti-apoptotic kinase pathways. FEBS Lett. 1998; 437: 112-16.
38. s expression, in a PI 3-kinase-and MAP kinase-dependent manner. Exp. Cell Res. 1998; 243: 213-21.
39. 39 Wang L, Ma W, Markovich R, Lee W-L, Wang PH. Insulin-like growth factor I modulates induction of apoplotic signalling in H9C2 cardiac muscle cells. Endocrinology 1998; 139: 1354-60.
40. 40 Butt AJ, Kumar S. Caspases: The molecular effectors of apoptosis. In: Lavin M, Watters D (eds). Signalling Pathways in Apoptosis. UK: Harwood Academic Publishers, 1999; 247-62.
41. 41 Jung Y-K, Miura M, Yuan J. Suppression of Interleukin-1β-converting enzyme-mediated cell death by insulin-like growth factor. J. Biol. Chem. 1996; 271: 51 12-17.
42. L function upstream of the ced-3-like apoptotic proteases. J. Biol. Chem. 1996; 271: 4573-6.
43. 43 McCarthy NJ, Whyte MKB, Gilbert CS, Evan GI. Inhibition of ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage or the bcl-2 homologue Bak. J. Cell Biol. 1907; 136: 215-27.
44. 44 Firth SM, Fanayan S, Benn D, Baxter RC. Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. Biochem. Biophys. Res. Commun. 1998; 246: 325-9.
45. 45 Cohen P, Lamson G, Okajima T, Rosenfeld RG. Transfection of the human IGFBP-3 gene into BALB/c fibroblasts -a model for the cellular functions of IGFBPs. Growth Reg. 1993; 3: 23-6.
46. 46 Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol. Endocrinol. 1995; 9: 361-7.
47. 47 Martin JL, Ballesteros M, Baxter RC. Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta 1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. Endocrinology 1992; 131: 1703-10.
48. 48 Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J. Biol. Chem. 1995; 270: 13 589-92.
49. 49 Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid-and transforming growth factor β2-induced growth inhibition in human breast cancer cells. Cancer Res. 1996; 56: 1545-50.
50. 50 Yateman ME, Claffey DC, Cwyfan Hughes SC, Frost VJ, Wass JA, Holly JM. Cytokines modulate the sensitivity of human fibroblasts to stimulation with insulin-like growth factor-I (IGF-I) by altering endogenous IGF-binding protein production. J. Endocrinol. 1993; 137: 151-9.
51. 51 Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor-α on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int. J. Oncol. 1998; 13: 865-9.
52. 52 Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J. Biol. Chem. 1996; 271: 1016-21.
53. 53 Nickerson T, Pollak M, Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5. Endocrinology 1998; 139: 807-10.
54. 54 Shen L, Glazer RI. Induction of apoptosis in glioblastoma cells by inhibition of protein kinase C and its association with the rapid accumulation of p53 and induction of the insulin-like growth factor-I binding protein 3. Biochem. Pharm. 1998; 55: 1711-19.
55. 55 Nickerson T, Huynh H, Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem. Biophys. Res. Commun. 1997; 237: 690-3.
56. 56 Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53-and IGF-independent mechanism. J. Biol. Chem. 1997; 272: 12 181-8.
57. 57 Oh Y, Muller HL, Pham H, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J. Biol. Chem. 1993; 268: 26 045-8.
58. 58 Leal SM, Liu Q, Huang SS, Huang JS. The type V transforming growth factor β receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol. Chem. 1998; 272: 20 572-6.
59. 59 Gill ZP, Perks CM, Newcomb PV, Holly JMP. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J. Biol. Chem. 1997; 272: 25 602-7.
60. 60 Jacques G, Noll K, Wegmann D et al. Nuclear localisation of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology 1997; 138: 1767-70.
61. 61 Li W, Fawcett J, Widmer HR, Fielder PJ, Rabkin R, Keller GA. Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. Endocrinology 1997; 138: 1763-6.
62. 62 Schedlich LJ, Young TY, Firth SM, Baxter RC. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J. Biol. Chem. 1998; 273: 18 347-52.
63. 63 Buckbinder L, Talbott R, Scizinger BR, Kley N. Gene regulation by temperature-sensitive p53 mutants: Identification of p53 response genes. Proc. Natl Acad. Sci. USA 1994; 91: 10 640-4.
64. 64 Buckbinder L, Talbott R, Velasco-Miguel S et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646-9.
65. 65 Bourdon J-C, Deguin-Chambon V, Lelong J-C et al. Further characterisation of the p53 responsive element identification of new candidate genes for trans-activation by p53. Oncogene 1997; 14: 85-94.
66. 66 Canman CE, Gilmer TM, Coutts SB, Kastan MB. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 1995; 9: 600-11.
67. 67 Rowan S, Ludwig RL, Haupt Y et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J. 1996; 15: 827-38.
68. 68 Friedlander P, Haupt Y, Prives C, Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 1996; 16: 4961-71.
69. 69 Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 1998; 16: 4952-60.
70. 70 Ryun KM, Vousden KH. Characterisation of structural p53 mutants which show selective detects in apoptosis but not cell cycle arrest. Mol. Cell. Biol. 1998; 18: 3692-8.
71. 71 Werner H, Karnieli F., Rauscher FJ, LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl Acad. Sci. USA 1998; 93: 8318-23.
72. 72 Ohlsson C, Kley N, Werner H, LeRoith D, p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: Interaction between p53 and Spl. Endocrinology 1998; 139: 1101-7.
73. 73 Prisco M, Hongo A, Rizzo MG, Sacchi A, Baserga R. The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol. Cell. Biol. 1998; 17: 1084-92.
74. 74 Zhang L, Kashanchi F, Zhan Q et al. Regulation of insulin-like growth factor II P3 promoter by p53: A potential mechanism for tumorigenesis. Cancer Res. 1996; 56: 1367-73.
75. 75 Baserga R. The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res. 1995; 55: 249-52.
76. 76 Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta 1997; 1332: F105-26.